Comparing new PET/CT tracers for neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a pathologist-confirmed well-differentiated neuroendocrine tumor (grades 1 or 2).
- You cannot have had a long-acting somatostatin analog in the last 4 weeks.
- You cannot have had PRRT (a type of radiation treatment) in the last 8 weeks.
- You cannot have another type of cancer, severe liver or kidney problems, an active infection, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This study uses a special PET scan called 18F-AlF-NOTA-Octreotide to get clear images of neuroendocrine tumors. It can help doctors see where the tumors are and how active they are, which may guide treatment decisions.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.